\nAllurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence.\n<\/p>\n
\n76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and increased to no greater than 5.0mg over the subsequent 2 months, considerably lower than standard dosing which can increase to 15mg. Tirzepatide therapy was continued for 8 months and final results were measured 2 months after discontinuation, for a total follow-up period of 12 months. Patients were followed using the AI-powered Virtual Care Suite as part of the Allurion Program.\n<\/p>\n
\nAfter 12 months, the average total body weight loss was 23%, and lean body mass as a percentage of total body weight increased by 14% from 62% to 70%. No patients discontinued early, and all patients remained adherent to tirzepatide for the duration of the study.\n<\/p>\n
\n\u201cThese results provide additional data that a combination approach with the Allurion Smart Capsule and GLP-1 medications has several advantages,\u201d said Dr. Luigi Flagiello, an expert in minimally invasive obesity care at Clinica Ruesch who oversaw this case series. \u201cBy combining these two therapies that have distinct physiological mechanisms of action and following patients closely using AI-powered virtual care, we can unlock increased weight loss while still increasing lean mass. By using lower doses of GLP-1s, we also show exceptional adherence to the GLP-1, which can lead to longer term weight maintenance.\u201d\n<\/p>\n
\nPrevious studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost1<\/sup> and have also shown that 30% of patients discontinue GLP-1 therapy within the first month and 58% discontinue before reaching a clinically meaningful health benefit2<\/sup>, due in part to side effects, dose escalation required for continued weight loss, and cost.\n<\/p>\n \nIn addition, a recent study published in JAMA Internal Medicine<\/i> shows that following withdrawal of tirzepatide, a higher degree of weight regain was associated with a greater reversal of initial improvements in waist circumference, blood pressure, non\u2013high-density lipoprotein cholesterol, glycemic parameters, and insulin resistance.3<\/sup><\/p>\n \n\u201cWe now have initial data for both low-dose semaglutide and tirzepatide in combination with the Allurion Program that addresses two significant challenges for GLP-1s\u2014muscle wasting and lack of adherence,\u201d said Dr. Shantanu Gaur, Founder and CEO of Allurion. \u201cA combination approach that leverages Allurion\u2019s full program\u2014which includes the Smart Capsule, our AI-powered Virtual Care Suite, and our behavior change program\u2014appears to be a compelling solution. We look forward to validating these results in a prospective clinical trial setting and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss.\u201d\n<\/p>\n \nAdditional data on the combination approach is being collected as part of this case series and is expected to be presented at upcoming medical meetings.\n<\/p>\n About Allurion
\n
<\/b>Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Smart Capsule, the world\u2019s first and only swallowable, ProcedurelessTM<\/sup> gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Smart Capsule is an investigational device in the United States.\n<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251125509141\/en\/1755824\/3\/Allurion_logo_HD.jpg\"){kind=logo}
<\/td>\n<\/tr>\n